BioStock: Stayble reaches important milestone – patient recruitment completed
Stayble Therapeutics recently recruited the last patient to the company’s phase IIb study with the drug candidate STA363 for discogenic chronic low back pain. The fact that the study is now fully recruited is in line with the communicated timetable to present study results by the end of 2023. The company’s CEO Andreas Gerward and CSO Anders Lehmann comments on the important milestone.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se